
Bay Area scientists work to restore sea star population devastated by pathogen
At the California Academy of Sciences in San Francisco, inside the Steinhart Aquarium, 7-year-old visitor Dylan Stewart was mesmerized by the Pycnopodia helianthoides, more commonly known as the sunflower sea star.
"I really like it," he exclaimed. "Because they're all going at different directions, kind of like a sunflower petal, and it's big like a sunflower."
The sunflower sea star can grow up to 24 arms, which explains the name. Dr. Rebecca Johnson, director at the Center for Biodiversity and Community Sciences and a scientist for the California Academy of Sciences, said she used to see lots of sunflower starfish at low tide off the California coast. But this is no longer the case.
"We went to places where you'd see hundreds of starfish in a day, but they were just completely gone," Johnson said.
Since 2013, a mysterious "wasting disease" epidemic has killed billions of sea stars, representing 26 species from Alaska to Baja Mexico.
"No one knew at the time what was causing it," Johnson said. "If they would ever recover, like we didn't know anything. It was just, it was just shocking."
The illness turns them to goo, essentially disintegrating them. More than 90% of sunflower sea stars are now wiped out. Now, a team of international scientists has solved the mystery.
After a four-year quest involving 20 experiments, the researchers have finally identified the pathogen. They honed in on the sea star's blood, called coelomic fluid.
"The culprit is a bacterium. It's a species of Vibrio," research scientist Melanie Prentice explained.
Vibrio is a genus of bacteria that can be devastating to coral, shellfish, and human beings. The species of Vibrio that is causing this epidemic in sea stars is known as V. pectenicida strain FHCF-3.
The successful efforts involved the Hakai Institute, the University of British Columbia, and the University of Washington. The scientists collaborated with The Nature Conservancy, The Tula Foundation, the U.S. Geological Survey's Western Fisheries Research Center, and the Washington Department of Fish and Wildlife.
As to what's driving the disease, Prentice pointed to warming waters.
"We have evidence that there is a link between increasing ocean temperatures and this sea star wasting disease epidemic," Prentice said.
The sunflower sea stars are voracious predators that feast on sea urchins. Without these starfish, sea urchins are then free to feast on valuable kelp forests. These forests provide habitat for marine creatures and store planet-warming carbon.
"They grazed or mowed down entire kelp forests," Prentice said. "So now places like Northern California have lost more than 95% of their kelp forest canopies."
The hope is now that scientists know the cause of the epidemic, they can screen for the pathogen. Some marine centers are already breeding sunflower sea stars with the hopes of one day reintroducing them in the wild, including at Cal Academy.
Aquarium curator Kylie Lev brought CBS News Bay Area behind the scenes to see how they are involved in conserving these critically endangered starfish. Along with the Aquarium of the Pacific, the Birch Aquarium, the San Diego Zoo Wildlife Alliance, and the Sunflower Star Laboratory, the scientists have successfully spawned and cross-fertilized sperm and eggs from male and female sea stars, created embryos, and are raising them.
Their efforts are identifying protocols and best practices, so that lab-spawned sunflower starfish may one day return to the wild.
"It is really important just to make sure in order for the population to sustain long-term, to have genetic diversity," Lev explained.
Some of the youngest juveniles are now on display at Steinhart Aquarium, a treat for the curious Dylan and his family.
"It's great that they finally figured out the cause; now it's hopefully figuring out how to get them repopulated," Dylan's father, Kyle Stewart, said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase 1/2 study nearing completion of enrollment; planning underway for a global Phase 3 confirmatory study On track to submit regulatory applications in 2025 to begin clinical testing of one to two additional TransportVehicleTM (TV)-enabled programs Preclinical research on ATV:Abeta program for Alzheimer's disease published in the journal Science SOUTH SAN FRANCISCO, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights. 'The FDA's priority review of our BLA for tividenofusp alfa and alignment on an accelerated approval path for DNL126 are key milestones highlighting the potential of our Transport Vehicle (TV) platform to catalyze a new class of blood-brain barrier-crossing therapeutics,' said Ryan Watts, Ph.D., CEO of Denali Therapeutics. 'With launch readiness in motion and a growing portfolio of TV-enabled enzyme, antibody, and oligonucleotide programs, Denali is poised to deliver meaningful treatments for people living with lysosomal, neurodegenerative, and other serious diseases.' Second Quarter 2025 and Recent Program Updates CLINICAL PROGRAMS Tividenofusp alfa (DNL310, ETV:IDS) for Hunter syndrome (MPS II) In July 2025, Denali announced that the U.S. Food and Drug Administration (FDA) accepted its Biologics License Application (BLA) for tividenofusp alfa for priority review, assigning a Prescription Drug User Fee Act (PDUFA) target action date of January 5, 2026. The BLA seeks accelerated approval based on a data package including results from the Phase 1/2 study in individuals with Hunter syndrome. Tividenofusp alfa is an investigational, next-generation enzyme replacement therapy designed to cross the blood-brain barrier (BBB) and deliver the iduronate-2-sulfatase (IDS) enzyme throughout the body and brain. The FDA previously granted tividenofusp alfa Breakthrough Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations. Denali continues to prepare for commercial launch and is conducting the Phase 2/3 COMPASS study to support global regulatory submissions. DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA) Today, Denali announced that it has reached alignment with the FDA's Center for Drug Evaluation and Research (CDER) that cerebrospinal fluid heparan sulfate (CSF HS) may be considered a reasonably likely surrogate endpoint to predict clinical benefit and may therefore be used to support accelerated approval of DNL126 for MPS IIIA. Additional 49-week data from the ongoing open-label Phase 1/2 study are consistent with previously announced 25-week data, demonstrating a significant reduction in CSF HS from baseline, including normalization, and a safety profile that supports continued development. Enrollment in the Phase 1/2 study is nearly complete, and planning is underway for a confirmatory global Phase 3 study. TAK-594/DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia Denali and Takeda continue their collaboration to develop DNL593, an investigational therapeutic designed to deliver progranulin across the BBB for the treatment of granulin (GRN) mutation-associated frontotemporal dementia (FTD-GRN). A Phase 1/2 study is ongoing. BIIB122/DNL151 (small molecule LRRK2 inhibitor) for the treatment of Parkinson's disease (PD) Denali and Biogen are co-developing LRRK2 inhibitors for Parkinson's disease. In May 2025, Biogen announced that the Phase 2b LUMA study of BIIB122 completed enrollment, with a readout expected in 2026. Denali is also conducting the Phase 2a BEACON study focused on LRRK2-associated PD. IND-ENABLING STAGE PROGRAMS Denali expects to submit regulatory applications to begin clinical testing of one to two TV-enabled programs each year over the next three years across its Enzyme TV (ETV), Antibody TV (ATV), and Oligonucleotide TV (OTV) franchises. The most advanced programs include: DNL952 (ETV:GAA) for Pompe disease; DNL111 (ETV:GCase) for Parkinson's/Gaucher disease; DNL622 (ETV:IDUA) for MPS I; DNL921 (ATV:Abeta) for Alzheimer's disease; DNL628 (OTV:MAPT) for Alzheimer's disease; and DNL422 (OTV:SNCA) for Parkinson's disease. Denali announced publication of preclinical data on ATV:Abeta in the August 7, 2025, issue of the journal Science. The research demonstrated that delivering an anti-amyloid beta antibody across the BBB using Denali's TV platform improved brain distribution and reduced the risk of amyloid-related imaging abnormality (ARIA) in a mouse model of Alzheimer's disease, compared to conventional antibody treatment. The findings suggest that TV platform-enabled brain delivery of immunotherapy bypasses amyloid-laden large vessels by traveling through smaller capillaries, offering a potential strategy to mitigate ARIA risk seen with first-generation anti-amyloid therapies. The Science article can be accessed here. Participation in Upcoming Investor Conferences Cantor Global Healthcare Conference 2025, September 3 - 5 (New York City) Morgan Stanley 23rd Annual Global Healthcare Conference, September 8 - 10 (New York City) Baird 2025 Global Healthcare Conference, September 9 - 10 (New York City) H.C. Wainwright 27th Annual Global Investment Conference, September 8 - 10 (New York City) Deutsche Bank BioPharm Corporate Day, September 18 - 19 (Austria) Stifel 2025 Healthcare Conference, November 11 - 13 (New York City) Jefferies Global Healthcare Conference, November 17 - 20 (London) Second Quarter 2025 Financial Results Net loss was $124.1 million for the quarter ended June 30, 2025, compared to net loss of $99.0 million for the quarter ended June 30, 2024. Total research and development expenses were $102.7 million for the quarter ended June 30, 2025, compared to $91.4 million for the quarter ended June 30, 2024. The increase of approximately $11.3 million was attributable to an increase of $7.3 million in TV program external research and development expenses, primarily driven by increased spend on multiple preclinical programs, and increases of $7.6 million and $6.2 million in other research and development expenses and personnel-related expenses, respectively, both driven by the commencement of operations at Denali's large molecule manufacturing facility in Salt Lake City, Utah. These increases were partially offset by a $9.8 million decrease in small molecule programs, primarily due to the winding down of activities related to the Phase 2/3 HEALEY ALS Platform Trial. General and administrative expenses were $32.3 million for the quarter ended June 30, 2025, compared to $25.2 million for the quarter ended June 30, 2024. The increase of $7.1 million was primarily driven by activities related to preparations for a potential commercial launch for tividenofusp alfa. Cash, cash equivalents, and marketable securities were approximately $977.4 million as of June 30, 2025. About Denali Therapeutics Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB, and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali's TV platform and its therapeutics and commercial potential; statements made by Denali's Chief Executive Officer; plans, timelines, and expectations relating to DNL310, including the PDUFA target action date and the timing, likelihood of, and scope of regulatory approval, the ongoing global Phase 2/3 COMPASS study and the likelihood of global approvals, and planned commercial launch; plans, timelines, and expectations related to DNL126, including enrollment in the ongoing Phase 1/2 study, plans regarding the confirmatory global Phase 3 study, planned engagement with the FDA, and the likelihood and scope of regulatory approvals; plans regarding DNL593 and the ongoing Phase 1/2 study; plans, timelines, and expectations regarding DNL151, including with respect to the ongoing Phase 2b LUMA study and the timing and likelihood of readout, and the ongoing Phase 2a BEACON study; plans and expectations for Denali's preclinical programs, including the timing of advancement to clinical studies; the findings from Denali's recent Science publication and their therapeutic potential regarding ARIA risk; Denali's participation in upcoming investor conferences; and Denali's future operating expenses and anticipated cash runway. All drugs currently being developed by Denali are investigational and have not received regulatory approval for any indication. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including but not limited to, risks related to: the impact of adverse economic conditions, tariffs, and inflation on Denali's business and operations; the occurrence of any event, change, or other circumstance that could give rise to the termination of Denali's agreements with Sanofi, Takeda, Biogen, or other collaborators; Denali's transition to a late-stage clinical drug development company; Denali's and its collaborators' ability to complete the development and, if approved, commercialization of its product candidates; Denali's and its collaborators' ability to enroll patients in its ongoing and future clinical trials; Denali's reliance on third parties for the manufacture and supply of its product candidates for clinical trials; Denali's dependence on successful development of its blood-brain barrier platform technology and its programs and product candidates; Denali's and its collaborators' ability to conduct or complete clinical trials on expected timelines; the risk that preclinical profiles of Denali's product candidates may not translate in clinical trials; the potential for clinical trials to differ from preclinical, early clinical, preliminary or expected results; the risk of significant adverse events, toxicities, or other undesirable side effects; the uncertainty that product candidates will receive regulatory approval necessary to be commercialized; Denali's ability to continue to create a pipeline of product candidates or commercialize products; developments relating to Denali's competitors and its industry, including competing product candidates and therapies; Denali's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Denali's strategic plans for its business, product candidates, and blood-brain barrier platform technology; Denali's ability to obtain additional capital to finance its operations, as needed; Denali's ability to accurately forecast future financial results and hedge against financial risk in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual Report and Quarterly Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 27, 2025 and May 6, 2025, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results, or to make changes in Denali's expectations, except as required by law. Denali Therapeutics Consolidated Statements of Operations(Unaudited)(In thousands, except share and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 102,696 $ 91,399 218,923 198,415 General and administrative 32,267 25,194 61,620 50,430 Total operating expenses 134,963 116,593 280,543 248,845 Gain from divestiture of small molecule programs — — — 14,537 Loss from operations (134,963 ) (116,593 ) (280,543 ) (234,308 ) Interest and other income, net 10,844 17,567 23,454 33,480 Net loss $ (124,119 ) $ (99,026 ) $ (257,089 ) $ (200,828 ) Net loss per share, basic and diluted $ (0.72 ) $ (0.59 ) $ (1.50 ) $ (1.26 ) Weighted average number of shares outstanding, basic and diluted 171,449,847 168,831,329 171,336,568 159,117,759 Denali Therapeutics Consolidated Balance Sheets(Unaudited)(In thousands) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 141,207 $ 174,960 Short-term marketable securities 757,745 657,371 Prepaid expenses and other current assets 35,754 32,105 Total current assets 934,706 864,436 Long-term marketable securities 78,463 359,373 Property and equipment, net 58,717 55,236 Finance lease right-of-use asset 50,363 47,533 Operating lease right-of-use asset 21,022 22,861 Other non-current assets 22,970 24,741 Total assets $ 1,166,241 $ 1,374,180 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 10,844 $ 11,137 Accrued compensation 12,068 24,728 Accrued clinical and other research & development costs 23,379 22,822 Accrued manufacturing costs 9,028 12,779 Operating lease liability, current 8,871 8,308 Deferred research and development funding liability, current 19,861 14,129 Other accrued costs and current liabilities 7,006 8,305 Total current liabilities 91,057 102,208 Operating lease liability, less current portion 32,110 36,673 Finance lease liability, less current portion 5,577 5,615 Deferred research funding and development liability, less current portion 10,444 — Total liabilities 139,188 144,496 Total stockholders' equity 1,027,053 1,229,684 Total liabilities and stockholders' equity $ 1,166,241 $ 1,374,180 Investor Contact:Laura Hansen, Media Contact:Erin Pattonepatton@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Geek Tyrant
4 hours ago
- Geek Tyrant
DUNE: PART THREE Will Reportedly Be Shot on Actual Film, a First for the Franchise — GeekTyrant
It looks like Denis Villeneuve is making a bold visual leap for Dune: Part Three , and fans of classic filmmaking should be pretty damn excited. The upcoming sequel, based on Frank Herbert's Dune Messiah , will reportedly be shot, at least in part, on actual film stock. That's a major shift from the digital workflow used for the first two Dune films, and it marks a significant aesthetic change for this ever-evolving sci-fi saga. The news first broke through Kodak Motion Picture Film's official Instagram account. Though the Story post has since expired, screenshots and reposts across the internet indicate that Dune: Part Three is making use of Kodak's film stock. While not yet officially confirmed, it lines up with a few other notable changes happening behind the scenes. For starters, Greig Fraser, the cinematographer behind the breathtaking visuals of Dune and Dune: Part Two , won't be returning. His work on The Batman: Part II meant he wasn't available, and Linus Sandgren is stepping in to shoot Part Three . Sandgren has a known preference for shooting on film. In fact, all of his major projects have been captured using film rather than digital. That choice would give Dune: Part Three a distinct visual feel, reinforcing Villeneuve's mission to make this film stand apart from the first two. As he previously said, the next installment 'will not be the completion of a trilogy. The first two movies were really a diptych. It was really a pair of movies that will be the adaptation of the first book. That's done and that's finished. If I do a third one, which is in the writing process, it's not like a trilogy. It's strange to say that, but if I go back there, it's to do something that feels different and has its own identity.' Villeneuve's desire for a fresh identity extends all the way down to the technical details. When shooting the first two films, the team used digital cameras, then printed the footage onto 35mm film and scanned it back into digital. Fraser explained the approach in an interview on the Go Creative Show podcast: 'It was an involved process that hasn't really happened before in commercial films. But it gave us the feeling we had been picturing—a certain texture that's painterly but feels timeless…The film has softened the edges of the digital. It gave us something that film acquisition couldn't give us, and it gave us something that digital acquisition couldn't give us.' Switching to full film acquisition could push that timeless aesthetic even further, offering a more organic, textured look for the harsh desert world of Arrakis. There's been some confusion around the camera formats lately. During a CNBC appearance, IMAX CEO Rich Gelfond said that Villeneuve would be shooting the entire film with IMAX cameras. That turned out to be inaccurate. IMAX quickly clarified that only select scenes will use IMAX cameras, which is standard practice for most modern blockbusters. Dune: Part Three began filming last month and is scheduled to hit theaters on December 18, 2026.

Associated Press
4 hours ago
- Associated Press
NASA's SpaceX Crew-10 Returns Safely After Completing Dozens of ISS National Lab-Sponsored Investigations
Astronauts wrap up mission after supporting research that could lead to new cancer treatments, more lifelike robotics, space debris removal, and more KENNEDY SPACE CENTER, Fla., Aug. 11, 2025 /PRNewswire/ -- After nearly six months onboard the International Space Station (ISS), the four astronauts of NASA's SpaceX Crew-10 mission have safely returned to Earth. This weekend's splashdown off the coast of California concludes a long-duration science expedition that supported dozens of investigations sponsored by the ISS National Laboratory®. NASA astronauts Anne McClain and NicholeAyers, Japan Aerospace Exploration Agency (JAXA) astronaut Takuya Onishi, and Roscosmos cosmonaut Kirill Peskov played a vital role in advancing science in space, contributing to biomedical research, physical and materials sciences, technology demonstrations, and student-led experiments. Their work helped push the boundaries of discovery in low Earth orbit to benefit life on Earth and support a sustainable and robust space economy. ISS National Lab-sponsored projects the crew worked on during their mission include the following: The ISS National Lab is proud to have partnered with NASA and international collaborators to enable this impactful space-based research for the benefit of humanity. The return of NASA's SpaceX Crew-10 mission marks the successful completion of another science expedition in the ongoing effort to leverage space as an innovation platform. To learn more about the science supported by the astronauts during this mission, visit our launch page. Download a high-resolution image for this release: Crew-10 Return About the International Space Station (ISS) National Laboratory: The International Space Station (ISS) is a one-of-a-kind laboratory that enables research and technology development not possible on Earth. As a public service enterprise, the ISS National Laboratory® allows researchers to leverage this multiuser facility to improve quality of life on Earth, mature space-based business models, advance science literacy in the future workforce, and expand a sustainable and scalable market in low Earth orbit. Through this orbiting national laboratory, research resources on the ISS are available to support non-NASA science, technology, and education initiatives from U.S. government agencies, academic institutions, and the private sector. The Center for the Advancement of Science in Space® (CASIS®) manages the ISS National Lab, under Cooperative Agreement with NASA, facilitating access to its permanent microgravity research environment, a powerful vantage point in low Earth orbit, and the extreme and varied conditions of space. To learn more about the ISS National Lab, visit our website. As a 501(c)(3) nonprofit organization, CASIS accepts corporate and individual donations to help advance science in space for the benefit of humanity. For more information, visit our donations page. View original content to download multimedia: SOURCE International Space Station National Lab